A legendary healthcare milestone reached when two firms join forces

The drug discovery and development company Mission Therapeutics ("Mission"), a worldwide research-driven biopharmaceutical company, announced today that DUB has been established as potential drug targets in the R&D relationship between the companies Alzheimer and Parkinson. The company's emphasis was on selectively inhibiting deubiquitylating enzymes (DUB), and abbVie ("AbbVie").

AbbVie has named the DUB b....